ALK抑制剂致非小细胞肺癌患者心律失常的研究进展

Research progress on arrhythmia caused by ALK inhibitors in patients with non-small cell lung cancer

随着精准医学的发展,靶向治疗在驱动基因阳性的晚期非小细胞肺癌(non-small cell lung cancer,NSCLC)患者中取得了良好疗效,其中间变性淋巴瘤激酶(anaplastic lymphoma kinase,ALK)因低突变率、高生存率被称为钻石突变。在真实世界的应用中,ALK抑制剂致患者心律失常的发病率远高于临床试验报道,严重的心律失常导致患者减药、停药、安装起搏器甚至猝死。本文将重点对ALK抑制剂相关心律失常的研究进展进行综述,以期提高临床医生对该不良反应的认识,指导临床医生用药。

With the development of precision medicine,targeted therapy has achieved good efficacy in patients with partial advanced non-small cell lung cancer(NSCLC)with a positive driver gene.Anaplastic lymphoma kinase(ALK)is called the diamond mutation due to its low mutation rate and high survival rate.In the general population,the incidence of arrhythmia caused by ALK inhibitors(ALKIs)is much higher than that reported in clinical trials.Severe arrhythmia can lead to drug reduction,drug withdrawal,pacemaker installa-tion,and even sudden death.This review focuses on the research progress of ALKIs related arrhythmia with the aim of improving clini-cians’understanding of the adverse effect and therefore guide the usage of medication.